MEMohamed Elkhodiry

Mohamed Elkhodiry

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mohamed Elkhodiry has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Bifunctional Surfaces With Immobilized Antibodies and Bioactive Peptides Mediate Selective Capture and Proliferation of Endothelial Colony‐Forming Cells

    by Hugo A. Level, Marc‐Antoine Campeau, Mohamed A. Elkhodiry, Gaétan Laroche, Jean‐François Tanguay, Corinne A. Hoesli

    Endothelial colony‐forming cells (ECFCs) are of significant interest in vascular biomaterials engineering and cell‐based therapies for cardiovascular diseases. Efficient isolation and expansion of ECFCs on polymeric surfaces either in vitro or in situ in the case of implants could significantly advance ECFC‐based therapies. We present a novel bifunctional surface modification strategy combining oriented antibodies and extracellular matrix‐derived peptides to selectively capture ECFCs on surfaces and then mediate firm adhesion, spreading and proliferation. Studies were conducted with anti‐CD309 antibodies and custom RGD peptides, previously shown to respectively enable ECFC capture and clonal expansion. To aid in oriented antibody immobilization on surfaces while modulating antibody‐RGD surface concentrations, Fc‐binding peptides and RGD peptides were co‐immobilized on aminated surfaces using click chemistry, followed by affinity‐mediated antibody immobilization. Bifunctional anti‐CD309 + RGD surfaces selectively captured ECFCs from a mixture with peripheral blood mononuclear cells in dynamic conditions. The presence of RGD peptides significantly enhanced cell spreading and proliferation, leading to additive effects on surface coverage under flow. Proof‐of‐concept studies demonstrated successful adaptation to 3D polystyrene microcarriers, showcasing potential scalability for clinical‐grade cell production. The surface modification scheme provides a versatile and clinically translatable platform for advancing ECFC‐based regenerative therapies.


  • Open Access

    A Fully Bioresorbable and Growth-Accommodating In-situ Tissue Engineered Valved Tube Prepared Using a Soft Elastomer

    by David Kalfa, Pierre Pouponneau, Axel T. Neffe, Bilal S. Ahmad, Margaux Pontailler, Kyun Thibaut, Paul J. Hommes-Schattmann, Marilys Blanchy, Mohamed A. Elkhodiry, Chloe Dujardin, et al.

    Children with congenital heart disease regularly require prosthetic valve implantation. Current prosthetic materials lack growth capacity and require re-sizing surgeries. We describe a bioresorbable polymeric blend that demonstrates excellent elastic behavior due to the presence of stable net points based on stereocomplexes. Valved tubes created by electrospinning were used for the reconstruction of the right ventricular outflow tract (RVOT). In a lamb model, valved and nonvalved tubes were compared to polymeric and biological standard tubes used in clinical practice (ePTFE Gore-Tex© and Contegra© tubes). No thrombus, stenosis, or diffuse calcification of the in-situ tissue-engineered tubes were observed, comparing favorably to control tubes. The implants were colonized with smooth muscle cells and endothelial cells with the neo-tissue demonstrating a mature organization. The valves were functional for up to 6 months but degraded thereafter. Importantly, both valved and un-valved tubes exhibited growth potential, with an overall growth between 26% and 38% at a 6-month follow-up. These results establish the proof-of-concept that a bioresorbable, stereocomplex-based polymeric conduit can accommodate growth and address the pressing need for long-term solutions in pediatric reconstruction surgeries.

  • Open Access

    Bioaffinity-based surface immobilization of antibodies to capture endothelial colony-forming cells

    by Mariève D. Boulanger, Hugo A. Level, Mohamed A. Elkhodiry, Omar S. Bashth, Pascale Chevallier, Gaétan Laroche, Corinne A. Hoesli

    Maximizing the re-endothelialization of vascular implants such as prostheses or stents has the potential to significantly improve their long-term performance. Endothelial progenitor cell capture stents with surface-immobilized antibodies show significantly improved endothelialization in the clinic. However, most current antibody-based stent surface modification strategies rely on antibody adsorption or direct conjugation via amino or carboxyl groups which leads to poor control over antibody surface concentration and/or molecular orientation, and ultimately bioavailability for cell capture. Here, we assess the utility of a bioaffinity-based surface modification strategy to immobilize antibodies targeting endothelial cell surface antigens. A cysteine-tagged truncated protein G polypeptide containing three Fc-binding domains was conjugated onto aminated polystyrene substrates via a bi-functional linking arm, followed by antibody immobilization. Different IgG antibodies were successfully immobilized on the protein G-modified surfaces. Covalent grafting of the protein G polypeptide was more effective than surface adsorption in immobilizing antibodies at high density based on fluorophore-labeled secondary antibody detection, as well as endothelial colony-forming cell capture through anti-CD144 antibodies. This work presents a potential avenue for enhancing the performance of cell capture strategies by using covalent grafting of protein G polypeptides to immobilize IgG antibodies.


  • A biomimetic multilayered polymeric material designed for heart valve repair and replacement

    by Mingze Sun, Mohamed Elkhodiry, Lei Shi, Yingfei Xue, Maryam H. Abyaneh, Alexander P. Kossar, Caroline Giuglaris, Samuel L. Carter, Richard L. Li, Emile Bacha, et al.


  • Open Access

    Bioaffinity-based surface-immobilization of antibodies to capture endothelial colony-forming cells

    by Mariève D. Boulanger, Mohamed A. Elkhodiry, Omar S. Bashth, Gaétan Laroche, Corinne A. Hoesli

    Maximizing the re-endothelialization of vascular implants such as prostheses or stents has the potential to significantly improve their long-term performance. Endothelial progenitor cell capture stents with surface-immobilized antibodies show significantly improved endothelialization in the clinic. However, most current antibody-based stent surface modification strategies rely on antibody adsorption or direct conjugation via amino or carboxyl groups which leads to poor control over antibody surface concentration and/or molecular orientation, and ultimately bioavailability for cell capture. Here, we assess the utility of a bioaffinity-based surface modification strategy consisting of a surface-conjugated cysteine-tagged protein G molecules that immobilize Immunoglobulin G (IgG) antibodies via the Fc domain to capture circulating endothelial colony-forming cells (ECFCs). The cysteine-tagged protein G was grafted onto aminated substrates at different concentrations as detected by an enzyme-linked immunosorbent assay and fluorescence imaging. Different IgG antibodies were successfully immobilized on the protein G-modified surfaces and higher antibody surface concentrations were achieved compared to passive adsorption methods. Surfaces with immobilized antibodies targeting endothelial surface proteins, such as CD144, significantly enhanced the capture of circulating ECFCs in vitro compared to surfaces with non-endothelial specific antibodies such as anti-CD14. This work presents a potential avenue for enhancing the clinical performance of vascular implants by using covalent grafting of protein G to immobilize IgG antibodies more effectively. Table of Contents: Antibody immobilization via surface-conjugated recombinant cysteine-protein G provides an effective approach to capture circulating therapeutic cells.

  • Open Access

    Surface grafting of Fc-binding peptides as a simple platform to immobilize and identify antibodies that selectively capture circulating endothelial progenitor cells

    by Omar S. Bashth, Mohamed A. Elkhodiry, Gaétan Laroche, Corinne A. Hoesli

    Antibody surface immobilization is a promising strategy to capture cells of interest from circulating fluids in vitro and in vivo. An application of particular interest in vascular interventions is to capture endothelial progenitor cells (EPCs) on the surface of stents to accelerate endothelialization. The clinical impact of EPC capture stents has been limited by the lack of efficient selective cell capture. Here, we describe a simple method to immobilize a variety of immunoglobulin G antibodies through their fragment crystallizable (Fc) regions via surface-conjugated RRGW peptides for cell capture applications. As an EPC capture model, peripheral blood endothelial colony-forming cells suspended in cell culture medium with up to 70% serum were captured by immobilized anti-CD144, anti-CD34 or anti-CD309 antibodies under laminar flow. The endothelial colony-forming cells were successfully enriched from a mixture with peripheral blood mononuclear cells using surfaces with anti-CD309 but not anti-CD45. This antibody immobilization approach holds great promise to engineer vascular biomaterials with improved EPC capture potential. The ease of immobilizing different antibodies using the same Fc-binding peptide surface grafting chemistry renders this platform suitable to screen antibodies that maximize cell capture efficiency and selectivity.


  • Open Access

    Isolating and Expanding Endothelial Progenitor Cells from Peripheral Blood on Peptide‐functionalized Polystyrene Surfaces

    by Mohamed Elkhodiry, Marieve Boulanger, Omar Bashth, Jean-François Tanguay, Gaétan Laroche, Corinne Hoesli

    The expansion of human peripheral blood endothelial progenitor cells to obtain therapeutically relevant endothelial colony forming cells (ECFCs) has been commonly performed on xeno‐derived extracellular matrix proteins. For cellular therapy applications, xeno‐free culture conditions are desirable to improve product safety and reduce process variability. We have previously described a novel fluorophore‐tagged RGD peptide (RGD‐TAMRA) that enhanced the adhesion of mature endothelial cells in vitro. To investigate whether this peptide can replace animal‐derived extracellular matrix proteins in the isolation and expansion of ECFCs, peripheral blood mononuclear cells from 22 adult healthy adult donors were seeded on RGD‐TAMRA‐modified polystyrene culture surfaces. Endothelial colony formation was significantly enhanced on RGD‐TAMRA‐modified surfaces compared to the unmodified control. No phenotypic differences were detected between ECFCs obtained on RGD‐TAMRA compared to ECFCs obtained on rat tail collagen‐coated surfaces. Compared to collagen‐coated surfaces and unmodified surfaces, RGD‐TAMRA surfaces promoted ECFC adhesion, cell spreading, and clonal expansion. This work presents a platform that allows for a comprehensive in vitro evaluation of peptide‐based biofunctionalization as a promising avenue for ex vivo ECFC expansion.

  • Isolating and expanding endothelial progenitor cells from peripheral blood on peptide‐functionalized polystyrene surfaces

    by Mohamed A. Elkhodiry, Mariève D. Boulanger, Omar Bashth, Jean‐François Tanguay, Gaétan Laroche, Corinne A. Hoesli

    The expansion of human peripheral blood endothelial progenitor cells to obtain therapeutically relevant endothelial colony forming cells (ECFCs) has been commonly performed on xeno‐derived extracellular matrix proteins. For cellular therapy applications, xeno‐free culture conditions are desirable to improve product safety and reduce process variability. We have previously described a novel fluorophore‐tagged RGD peptide (RGD‐TAMRA) that enhanced the adhesion of mature endothelial cells in vitro. To investigate whether this peptide can replace animal‐derived extracellular matrix proteins in the isolation and expansion of ECFCs, peripheral blood mononuclear cells from 22 adult healthy adult donors were seeded on RGD‐TAMRA‐modified polystyrene culture surfaces. Endothelial colony formation was significantly enhanced on RGD‐TAMRA‐modified surfaces compared to the unmodified control. No phenotypic differences were detected between ECFCs obtained on RGD‐TAMRA compared to ECFCs obtained on rat tail collagen‐coated surfaces. Compared to collagen‐coated surfaces and unmodified surfaces, RGD‐TAMRA surfaces promoted ECFC adhesion, cell spreading, and clonal expansion. This work presents a platform that allows for a comprehensive in vitro evaluation of peptide‐based biofunctionalization as a promising avenue for ex vivo ECFC expansion.


  • Targeting the Folate Receptor: Effects of Conjugating Folic Acid to DOX Loaded Polymeric Micelles

    by Mohamed A. Elkhodiry, Ghaleb A. Husseini, Diana Velluto

    In this paper, we report on a potential cancer drug delivery system that utilizes the ligand targeting of the folate receptor. Our drug delivery system consists of Pluronic-P105 micelles, targeted with folic acid moieties. A melanoma folate positive (FR+) (B16-F10), and a fibroblast folate negative (FR-) (NIH-3T3) cell lines are used to compare the cellular accumulation of a chemotherapeutic drug (Doxorubicin) when the delivery is mediated by folated Pluronic P105 micelles. In order to obtain a proper comparison, we corrected for the quenching of Doxorubicin by folic acid molecules and illustrated the significant effect of quenching on the analysis of similar systems. Results show an 80% increase in the accumulation of the antineoplastic agent in the FR+ cell line, when compared to the FR- cell line, thus providing evidence that the efficacy of Pluronic micelles, as drug delivery vehicles, can be enhanced via folic acid targeting.


  • Ultrasound-induced doxorubicin release from folate-targeted and non-targeted P105 micelles: a modeling study

    by Ana M. Martins, Rafeeq Tanbour, Mohammed A. Elkhodiry, Ghaleb A. Husseini

    The aim of this work is to study the kinetics of ultrasound (70 kHz) – using a kinetic model that takes into account cavitation events and drug re-encapsulation upon the cessation of the acoustic field. The simulation allowed the determination of three parameters α , β and λ that define the release and re-encapsulation behavior of this drug delivery system (DDS). The results showed that the drug release increased with increasing power density, as evidenced by the correlation between α and power density. The micelle re-assembly, quantified by the parameter β , also increased with increasing power density. The parameter λ , which is associated with the initial phase of the release process, showed a constant value regardless of the power density. The significance of these results was discussed. Additionally, a comparison between these parameters in folate-targeted and non-targeted micelles showed statistically significant differences for several power densities examined. A better understanding of the kinetics involved in this DDS is very important for the determination of the optimum ultrasound parameters to be used in future in vitro and in vivo experiments.